Skip Navigation
Skip to contents

Ann Coloproctol : Annals of Coloproctology

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
15 "Yong Beom Cho"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Colorectal cancer
Public effect of the 2022 Colorectal Cancer Awareness Campaign delivered through a metaverse platform
Tae-Gyun Lee, Gil-Hyeon Song, Hong-min Ahn, Heung-Kwon Oh, Moonkyoung Byun, Eon Chul Han, Sohyun Kim, Chang Woo Kim, Hye Jin Kim, Samin Hong, Kee-Ho Song, Chan Wook Kim, Yong Beom Cho, on behalf of the Public Relations Committee of the Korean Society of Coloproctology (KSCP)
Ann Coloproctol. 2024;40(2):145-153.   Published online April 28, 2023
DOI: https://doi.org/10.3393/ac.2023.00122.0017
  • 9,121 View
  • 137 Download
  • 1 Web of Science
  • 2 Citations
Graphical AbstractGraphical Abstract AbstractAbstract PDF
Purpose
The Korean Society of Coloproctology has been conducting Colorectal Cancer Awareness Campaign, also known as the Gold Ribbon Campaign, every September since 2007. The 2022 campaign was held through a metaverse platform targeting the younger age group under the slogan of raising awareness of early-onset colorectal cancer (CRC). This study aimed to analyze the impact of the 2022 campaign on a metaverse platform.
Methods
Anonymized survey data were collected from participants in the metaverse campaign from September 1 to 15, 2022. The satisfaction score of the participants was evaluated by sex, age group, and previous campaign participation status.
Results
During the campaign, 2,770 people visited the metaverse. Among them, 455 people participated in the survey (response rate, 16.4%). Approximately 95% of the participants reported being satisfied with the information provided by the campaign, understood the necessity of undergoing screening for and prevention of early-onset CRC, and were familiar with the structure of the metaverse. The satisfaction score for campaign information tended to decrease as the participants’ age increased. When the participants’ overall level of satisfaction with the metaverse platform was assessed, teenagers scored particularly lower than the other age groups. The satisfaction scores for CRC information provided in the metaverse, as well as the scores for recognizing the seriousness and necessity of screening for early-onset CRC, indicated a high positive tendency (P<0.001).
Conclusion
Most of the 2022 Gold Ribbon Campaign participants were satisfied with the metaverse platform. Medical society should pay attention to increasing participation in and satisfaction with future public campaigns.

Citations

Citations to this article as recorded by  
  • #CRCandMe: results of a pre-post quasi-experimental study of a mass media campaign to increase early-onset colorectal cancer awareness in Utah and Wisconsin
    Ami E Sedani
    American Journal of Cancer Research.2024; 14(8): 3873.     CrossRef
  • Metaverse in surgery — origins and future potential
    Enrico Checcucci, Alessandro Veccia, Stefano Puliatti, Pieter De Backer, Pietro Piazza, Karl-Friedrich Kowalewski, Severin Rodler, Mark Taratkin, Ines Rivero Belenchon, Loic Baekelandt, Sabrina De Cillis, Alberto Piana, Ahmed Eissa, Juan Gomez Rivas, Giov
    Nature Reviews Urology.2024;[Epub]     CrossRef
Minimally invasive surgery
Learning curve for single-port robot-assisted colectomy
Moon Suk Choi, Seong Hyeon Yun, Sung Chul Lee, Jung Kyong Shin, Yoon Ah Park, Jungwook Huh, Yong Beom Cho, Hee Cheol Kim, Woo Yong Lee
Ann Coloproctol. 2024;40(1):44-51.   Published online December 20, 2022
DOI: https://doi.org/10.3393/ac.2022.00745.0106
  • 2,618 View
  • 192 Download
  • 2 Web of Science
  • 2 Citations
AbstractAbstract PDF
Purpose
Since the introduction of robotic surgery, robots for colorectal cancer have replaced laparoscopic surgery, and a single-port robot (SPR) platform has been launched and is being used to treat patients. We analyzed the learning curve and initial complications of using an SPR platform in colorectal cancer surgery.
Methods
We reviewed 39 patients who underwent SPR colectomy from April to October 2019. All surgeries were performed by the same surgeon using an SPR device. A learning curve was generated using the cumulative sum methodology to assess changes in total operation time, docking time, and surgeon console time. We grouped the patients into 3 groups according to the time period: the first 11 were phase 1, the next 11 were phase 2, and the last 17 were phase 3.
Results
The mean age of the patients was 61.28±13.03 years, and they had a mean body mass index of 23.79±2.86 kg/m2. Among the patients, 23 (59.0%) were male, and 16 (41.0%) were female. The average operation time was 186.59±51.30 minutes, the average surgeon console time was 95.49±35.33 minutes, and the average docking time (time from skin incision to robot docking) was 14.87±10.38 minutes. The surgeon console time differed significantly among the different phases (P<0.001). Complications occurred in 8 patients: 2 ileus, 2 postoperation hemoglobin changes, 3 urinary retentions, and 1 complicated fluid collection.
Conclusion
In our experience, the learning curve for SPR colectomy was achieved after the 18th case.

Citations

Citations to this article as recorded by  
  • Da Vinci single-port robotic system current application and future perspective in general surgery: A scoping review
    Francesco Celotto, Niccolò Ramacciotti, Alberto Mangano, Giacomo Danieli, Federico Pinto, Paula Lopez, Alvaro Ducas, Jessica Cassiani, Luca Morelli, Gaya Spolverato, Francesco Maria Bianco
    Surgical Endoscopy.2024; 38(9): 4814.     CrossRef
  • Wristed articulated instrumentation for single‐incision plus one‐port laparoscopic surgery for obstructed sigmoid colon cancer—A video vignette
    Sung Uk Bae
    Colorectal Disease.2024; 26(9): 1782.     CrossRef
Malignant disease,Colorectal cancer
Proteomic identification of arginine-methylated proteins in colon cancer cells and comparison of messenger RNA expression between colorectal cancer and adjacent normal tissues
Yongchul Lim, Da Young Gang, Woo Yong Lee, Seong Hyeon Yun, Yong Beom Cho, Jung Wook Huh, Yoon Ah Park, Hee Cheol Kim
Ann Coloproctol. 2022;38(1):60-68.   Published online January 27, 2022
DOI: https://doi.org/10.3393/ac.2020.00899.0128
  • 3,680 View
  • 135 Download
  • 3 Web of Science
  • 4 Citations
AbstractAbstract PDFSupplementary Material
Purpose
Identification of type I protein arginine methyltransferase (PRMT) substrates and their functional significance during tumorigenesis is becoming more important. The present study aimed to identify target substrates for type I PRMT using 2-dimensional (2D) gel electrophoresis (GE) and 2D Western blotting (WB).
Methods
Using immunoblot analysis, we compared the expression of type I PRMTs and endogenous levels of arginine methylation between the primary colorectal cancer (CRC) and adjacent noncancerous tissues paired from the same patient. To identify arginine-methylated proteins in HCT116 cells, we carried out 2D-GE and 2D-WB with a type I PRMT product-specific antibody (anti-dimethyl-arginine antibody, asymmetric [ASYM24]). Arginine-methylated protein spots were identified by mass spectrometry, and messenger RNA (mRNA) levels corresponding to the identified proteins were analyzed using National Center for Biotechnology Information (NCBI) microarray datasets between the primary CRC and noncancerous tissues.
Results
Type I PRMTs and methylarginine-containing proteins were highly maintained in CRC tissues compared to noncancerous tissues. We matched 142 spots using spot analysis software between a Coomassie blue (CBB)-stained 2D gel and 2D-WB, and we successfully identified 7 proteins that reacted with the ASYM24 antibody: CACYBP, GLOD4, MAPRE1, CCT7, TKT, CK8, and HSPA8. Among these proteins, the levels of 4 mRNAs including MAPRE1, CCT7, TKT, and HSPA8 in CRC tissues showed a statistically significant increase compared to noncancerous tissues from patients using the NCBI microarray datasets.
Conclusion
Our results indicate that the method shown here is useful in identifying arginine-methylated proteins, and significance of arginine modification in the proteins identified here should be further identified during CRC development.

Citations

Citations to this article as recorded by  
  • Multi-omics data-based analysis characterizes molecular alterations of the vesicle genes in human colorectal cancer
    Xi Wang
    American Journal of Cancer Research.2024; 14(3): 1402.     CrossRef
  • Expression of GLOD4 in the Testis of the Qianbei Ma Goat and Its Effect on Leydig Cells
    Jinqian Wang, Xiang Chen, Wei Sun, Wen Tang, Jiajing Chen, Yuan Zhang, Ruiyang Li, Yanfei Wang
    Animals.2024; 14(17): 2611.     CrossRef
  • Sperm protein antigen 17 and Sperm flagellar 1 cancer testis antigens are expressed in a rare case of ciliated foregut cyst of the common hepatic duct
    Fabio Grizzi, Maurizio Chiriva-Internati, Elena Miranda, Roxana Zaharie, Nadim Al Hajjar, Florin Zaharie, Cristina Díaz Del Arco, M.Jesús Fernández-Aceñero, Robert S. Bresalier, Emil Moiş
    Pathology - Research and Practice.2023; 247: 154546.     CrossRef
  • Inflammatory Response Markers as Predictors of Colorectal Cancer Prognosis
    Minsung Kim, Il Tae Son, Bo Young Oh
    The Ewha Medical Journal.2023;[Epub]     CrossRef
Malignant disease,Colorectal cancer,Benign diesease & IBD,Biomarker & risk factor
Molecular characterization of dysplasia-initiated colorectal cancer with assessing matched tumor and dysplasia samples
Sungwon Jung, Jong Lyul Lee, Tae Won Kim, Jongmin Lee, Yong Sik Yoon, Kil Yeon Lee, Ki-hwan Song, Chang Sik Yu, Yong Beom Cho
Ann Coloproctol. 2022;38(1):72-81.   Published online November 17, 2021
DOI: https://doi.org/10.3393/ac.2021.00290.0041
  • 3,555 View
  • 125 Download
  • 2 Web of Science
  • 2 Citations
AbstractAbstract PDF
Purpose
Ulcerative colitis (UC) is known to have an association with the increased risk of colorectal cancer (CRC), and UC-associated CRC does not follow the typical progress pattern of adenoma-carcinoma. The aim of this study is to investigate molecular characteristics of UC-associated CRC and further our understanding of the association between UC and CRC.
Methods
From 5 patients with UC-associated CRC, matched normal, dysplasia, and tumor specimens were obtained from formalin-fixed paraffin-embedded (FFPE) samples for analysis. Genomic DNA was extracted and whole exome sequencing was conducted to identify somatic variations in dysplasia and tumor samples. Statistical analysis was performed to identify somatic variations with significantly higher frequencies in dysplasia-initiated tumors, and their relevant functions were investigated.
Results
Total of 104 tumor mutation genes were identified with higher mutation frequencies in dysplasia-initiated tumors. Four of the 5 dysplasia-initiated tumors (80.0%) have TP53 mutations with frequent stop-gain mutations that were originated from matched dysplasia. APC and KRAS are known to be frequently mutated in general CRC, while none of the 5 patients have APC or KRAS mutation in their dysplasia and tumor samples. Glycoproteins including mucins were also frequently mutated in dysplasia-initiated tumors.
Conclusion
UC-associated CRC tumors have distinct mutational characteristics compared to typical adenoma-carcinoma tumors and may have different cancer-driving molecular mechanisms that are initiated from earlier dysplasia status.

Citations

Citations to this article as recorded by  
  • Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus R0 resection for resectable colorectal cancer with peritoneal metastases and low peritoneal cancer index scores: a collaborative observational study from Korea and Japan
    Daichi Kitaguchi, Eun Jung Park, Seung Hyuk Baik, Shoma Sasaki, Yuichiro Tsukada, Masaaki Ito
    International Journal of Surgery.2024; 110(1): 45.     CrossRef
  • Impact of Postoperative Naples Prognostic Score to Predict Survival in Patients with Stage II–III Colorectal Cancer
    Su Hyeong Park, Hye Seung Woo, In Kyung Hong, Eun Jung Park
    Cancers.2023; 15(20): 5098.     CrossRef
Technical Note
Malignant disease, Rectal cancer,Minimally invasive surgery
Single-port robot-assisted abdominoperineal resection: a case review of the first four experiences
Moon Suk Choi, Seong Hyeon Yun, Jung Kyong Shin, Yoon Ah Park, Jung Wook Huh, Yong Beom Cho, Hee Cheol Kim, Woo Yong Lee
Ann Coloproctol. 2022;38(1):88-92.   Published online October 18, 2021
DOI: https://doi.org/10.3393/ac.2021.00395.0056
  • 3,220 View
  • 126 Download
  • 5 Web of Science
  • 5 Citations
AbstractAbstract PDF
Recently, abdominoperineal resection (APR) using a robot has been demonstrated in other studies. However, there has been no report on APR for rectal cancer using the single-port robot (SPR) platform. In response to this research gap, we described the clinical experience of APR using a SPR. From April 2019 to March 2020, APR using a SPR platform was performed in a total of 4 patients. Three patients had a transumbilical approach, and 1 patient had a transstoma site approach. The average operation time was 307 minutes, and the patient docking time to the SPR platform was 133.5 minutes. There were no complications during the operation, and no laparoscopy or open conversion. No reoperation occurred within 30 days. Mild postoperative complications occurred in 2 patients. We found that APR has safety and feasibility in surgery using an SPR platform. There was no intraoperative event and severe postoperative complications.

Citations

Citations to this article as recorded by  
  • Single-incision laparoscopic total extraperitoneal inguinal-hernia repair using the new articulating instruments: A video vignette
    Chul Seung Lee, Gwan Chul Lee, Choon Sik Chung, Dong Keun Lee
    Asian Journal of Surgery.2024; 47(8): 3586.     CrossRef
  • Single-incision robotic colorectal surgery with the da Vinci SP® surgical system: initial results of 50 cases
    H. S. Kim, B.-Y. Oh, C. Cheong, M. H. Park, S. S. Chung, R.-A. Lee, K. H. Kim, G. T. Noh
    Techniques in Coloproctology.2023; 27(7): 589.     CrossRef
  • Short-term outcomes of single-incision robotic colectomy versus conventional multiport laparoscopic colectomy for colon cancer
    Ho Seung Kim, Bo-Young Oh, Soon Sup Chung, Ryung-Ah Lee, Gyoung Tae Noh
    Journal of Robotic Surgery.2023; 17(5): 2351.     CrossRef
  • Short-term outcomes of da Vinci SP versus Xi for colon cancer surgery: a propensity-score matching analysis of multicenter cohorts
    Jin-Min Jung, Young Il Kim, Yong Sik Yoon, Songsoo Yang, Min Hyun Kim, Jong Lyul Lee, Chan Wook Kim, In Ja Park, Seok-Byung Lim, Chang Sik Yu
    Journal of Robotic Surgery.2023; 17(6): 2911.     CrossRef
  • Surgical Techniques for Transanal Local Excision for Early Rectal Cancer
    Gyoung Tae Noh
    The Ewha Medical Journal.2023;[Epub]     CrossRef
Original Articles
Special issue, Malignant disease, Rectal cancer,Colorectal cancer,Epidemiology & etiology
Has the COVID-19 Pandemic Caused Upshifting in Colorectal Cancer Stage?
Ji Ha Lim, Woo Yong Lee, Seong Hyeon Yun, Hee Cheol Kim, Yong Beom Cho, Jung Wook Huh, Yoon Ah Park, Jung Kyong Shin
Ann Coloproctol. 2021;37(4):253-258.   Published online August 9, 2021
DOI: https://doi.org/10.3393/ac.2021.00269.0038
  • 3,965 View
  • 90 Download
  • 19 Web of Science
  • 19 Citations
AbstractAbstract PDF
Purpose
Coronavirus disease 2019 (COVID-19) has affected many parts of daily life and healthcare, including cancer screening and diagnosis. The purpose of this study was to determine whether there was an upshift in the colorectal cancer stage at diagnosis due to delays related to the COVID-19 outbreak.
Methods
From January to June of each year from 2017 to 2020, a total of 3,229 patients who were first diagnosed with colorectal cancer were retrospectively reviewed. Those enrolled from 2017 to 2019 were classified as the ‘pre-COVID’ group, and those enrolled in 2020 were classified as the ‘COVID’ group. The primary outcome was the rate of stage IV disease at the time of diagnosis.
Results
There was no statistically significant difference in the proportion of stage IV patients between the pre-COVID and COVID groups (P=0.19). The median preoperative carcinoembryonic antigen level in the COVID group was higher than in the pre-COVID group in all stages (all P<0.05). In stage I, II patients who underwent radical surgery, the lymphatic invasion was more presented in COVID patients (P=0.009).
Conclusion
We did not find significant stage upshifting in colorectal cancer during the COVID-19 outbreak. However, there were more initially unresectable stage IV colorectal cancer patients with a low conversion rate to resectable status, and more patients had factors related to poor prognosis. These results may become more apparent over time, so it is vital not to neglect cancer screening to not delay the diagnosis during the COVID-19 epidemic.

Citations

Citations to this article as recorded by  
  • The impact of COVID-19 on patients diagnosed with melanoma, breast, and colorectal cancer
    Danielle Hanuschak, Mallori DePiero, Melissa DeMoraes, Shamoore Bailly, Muni Rubens, Paul Lindeman, Michael Zinner, Geoffrey Young
    The American Journal of Surgery.2024; 229: 36.     CrossRef
  • The global pandemic's second deadly hit: cancer care
    Emma Bradley, Magge Deepa
    The American Journal of Surgery.2024; 229: 34.     CrossRef
  • Trends in the Stage Distribution of Colorectal Cancer During the COVID-19 Pandemic in Japan: A Nationwide Hospital-claims Data Analysis
    Masato Ota, Kohei Taniguchi, Mitsuhiro Asakuma, Sang-Woong Lee, Yuri Ito
    Journal of Epidemiology.2024; 34(7): 356.     CrossRef
  • Inadvertent laparoscopic lavage of perforated colon cancer: a systematic review
    Mahir Gachabayov, Agon Kajmolli, Luis Quintero, Daniel M. Felsenreich, Dorin E. Popa, Dejan Ignjatovic, Roberto Bergamaschi
    Langenbeck's Archives of Surgery.2024;[Epub]     CrossRef
  • Impact of the Sars-Cov-2 outbreak on the initial clinical presentation of new solid cancer diagnoses: a systematic review and meta-analysis
    Simon Marty, Guillaume Lamé, Etienne Guével, Sonia Priou, Gilles Chatellier, Christophe Tournigand, Emmanuelle Kempf
    BMC Cancer.2024;[Epub]     CrossRef
  • Measuring the impact of COVID-19 on cancer survival using an interrupted time series analysis
    Pascal Lambert, Katie Galloway, Allison Feely, Oliver Bucher, Piotr Czaykowski, Pamela Hebbard, Julian O Kim, Marshall Pitz, Harminder Singh, Maclean Thiessen, Kathleen M Decker
    JNCI Cancer Spectrum.2024;[Epub]     CrossRef
  • Decreased Positive Fecal Occult Blood Tests and Delayed Medical Presentation for Colorectal Cancer during the Initial COVID-19 Pandemic Period: A Single-center Experience
    Tadataka Takagi, Fumikazu Koyama, Hiroyuki Kuge, Yosuke Iwasa, Takeshi Takei, Tomomi Sadamitsu, Kosuke Fujimoto, Suzuka Harada, Takashi Tamura, Goki Ejiri, Chihiro Yoshikawa, Masayuki Sho
    Journal of the Anus, Rectum and Colon.2024; 8(3): 188.     CrossRef
  • Impact of COVID-19 Pandemic on the Clinical and Pathologic Characteristics of Colorectal Cancer: A Retrospective Multicenter Study in South Korea
    Jae Hyun Kang, Il Tae Son, Sang Nam Yoon, Jin Soo Ihm, Byung Mo Kang, Jong Kim
    Cancer Management and Research.2024; Volume 16: 1131.     CrossRef
  • The COVID-19 pandemic's impact on prostate cancer screening and diagnosis in Korea
    Byeong Jin Kang, Kyung Hwan Kim, Hong Koo Ha
    Kosin Medical Journal.2023; 38(3): 193.     CrossRef
  • Measuring the impact of the COVID‐19 pandemic on colorectal cancer presentation: a retrospective comparative study
    Kirsten Fullard, Daniel Steffens, Michael Solomon, Joo‐Shik Shin, Cherry Koh
    ANZ Journal of Surgery.2023; 93(12): 2951.     CrossRef
  • Influence of the COVID-19 Pandemic on the Treatment Patterns and Outcomes of Colorectal Cancer
    In Ja Park
    The Ewha Medical Journal.2023;[Epub]     CrossRef
  • Colorectal Surgery in the COVID-19 Era: A Systematic Review and Meta-Analysis
    Nikolaos Pararas, Anastasia Pikouli, Dimitrios Papaconstantinou, Georgios Bagias, Constantinos Nastos, Andreas Pikoulis, Dionysios Dellaportas, Panagis Lykoudis, Emmanouil Pikoulis
    Cancers.2022; 14(5): 1229.     CrossRef
  • Short-Term Impact of Temporary Shutdown of a University-Affiliated Hospital on Patients With Colorectal Cancer During the Coronavirus Disease 2019 Pandemic
    Youn Young Park, Jaeim Lee, Kil-yong Lee, Seong Taek Oh
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • Surgical safety in the COVID-19 era: present and future considerations
    Young Il Kim, In Ja Park
    Annals of Surgical Treatment and Research.2022; 102(6): 295.     CrossRef
  • The effect of the COVID-19 pandemic on the outcomes of surgically treated colorectal diseases: a retrospective cohort study
    Gülten Çiçek Okuyan, Melih Yıldırım
    Annals of Surgical Treatment and Research.2022; 103(2): 104.     CrossRef
  • Clinical presentation, management, screening and surveillance for colorectal cancer during the COVID-19 pandemic
    Sami Akbulut, Abdirahman Sakulen Hargura, Ibrahim Umar Garzali, Ali Aloun, Cemil Colak
    World Journal of Clinical Cases.2022; 10(26): 9228.     CrossRef
  • Epidemiology, risk factors, and prevention of colorectal cancer
    Kyung Uk Jung, Hyung Ook Kim, Hungdai Kim
    Journal of the Korean Medical Association.2022; 65(9): 549.     CrossRef
  • Epidemiology, Risk Factors, and Prevention of Colorectal Cancer-An English Version
    Kyung Uk Jung, Hyung Ook Kim, Hungdai Kim
    Journal of the Anus, Rectum and Colon.2022; 6(4): 231.     CrossRef
  • No evidence of delay in colorectal cancer diagnosis during the COVID-19 pandemic in Gwangju and Jeonnam, Korea
    Hye-Yeon Kim, Min-Gyeong Kim, Mi-Ran Kang, Jeong-Ho Yang, Min-Ho Shin, Sun-Seog Kweon
    Epidemiology and Health.2022; 44: e2022092.     CrossRef
Malignant disease,Rectal cancer,Prognosis and adjuvant therapy,Colorectal cancer
Clinical Outcomes of Neoadjuvant Chemotherapy in Colorectal Cancer Patients With Synchronous Resectable Liver Metastasis: A Propensity Score Matching Analysis
Sung Hae Park, Jung Kyong Shin, Woo Yong Lee, Seong Hyeon Yun, Yong Beom Cho, Jung Wook Huh, Yoon Ah Park, Jin Seok Heo, Gyu Seong Choi, Seung Tae Kim, Young Suk Park, Hee Cheol Kim
Ann Coloproctol. 2021;37(4):244-252.   Published online June 29, 2021
DOI: https://doi.org/10.3393/ac.2020.00710.0101
  • 6,300 View
  • 88 Download
  • 14 Web of Science
  • 14 Citations
AbstractAbstract PDF
Purpose
The survival benefit of neoadjuvant chemotherapy (NAC) prior to surgical resection in colorectal cancer with liver metastases (CRCLM) patients remains controversial. The aim of this study was to compare overall outcome of CRCLM patients who underwent NAC followed by surgical resection versus surgical treatment first.
Methods
We retrospectively analyzed 429 patients with stage IV colorectal cancer with synchronous liver metastases who underwent simultaneous liver resection between January 2008 and December 2016. Using propensity score matching, overall outcome between 60 patients who underwent NAC before surgical treatment and 60 patients who underwent surgical treatment first was compared.
Results
Before propensity score matching, metastatic cancer tended to involve a larger number of liver segments and the primary tumor size was bigger in the NAC group than in the primary resection group, so that a larger percentage of patients in the NAC group underwent major hepatectomy (P<0.001). After propensity score matching, demographic features and pathologic outcomes showed no significant differences between the 2 groups. In addition, there was no significant difference in short-term recovery outcomes such as postoperative morbidity (P=0.603) and oncologic outcome, including 3-year overall survival rate (P=0.285) and disease-free survival rate (P=0.730), between the 2 groups.
Conclusion
NAC prior to surgical treatment in CRCLM is considered a safe treatment that does not increase postoperative morbidity, and its impact on oncologic outcome was not inferior.

Citations

Citations to this article as recorded by  
  • Colon cancer: the 2023 Korean clinical practice guidelines for diagnosis and treatment
    Hyo Seon Ryu, Hyun Jung Kim, Woong Bae Ji, Byung Chang Kim, Ji Hun Kim, Sung Kyung Moon, Sung Il Kang, Han Deok Kwak, Eun Sun Kim, Chang Hyun Kim, Tae Hyung Kim, Gyoung Tae Noh, Byung-Soo Park, Hyeung-Min Park, Jeong Mo Bae, Jung Hoon Bae, Ni Eun Seo, Cha
    Annals of Coloproctology.2024; 40(2): 89.     CrossRef
  • Survival of patients with colorectal liver metastases treated with and without preoperative chemotherapy: Nationwide propensity score-matched study
    Michelle.R. de Graaff, Joost M. Klaase, Ronald M. van Dam, Koert F.D. Kuhlmann, Geert Kazemier, Rutger-Jan Swijnenburg, Arthur K.E. Elfrink, Cees Verhoef, J.Sven Mieog, Peter B. van den Boezem, Paul Gobardhan, Arjen M. Rijken, Daan J. Lips, Wouter G.K. Le
    European Journal of Surgical Oncology.2023; 49(9): 106932.     CrossRef
  • Laparoscopic right hemicolectomy with aortocaval lymphadenectomy, and pelvic peritoneum partial resection for ascending colon cancer
    Hannah Kim, An Na Seo, Soo Yeun Park
    Annals of Coloproctology.2023; 39(3): 283.     CrossRef
  • Fluorescence-guided colorectal surgery: applications, clinical results, and protocols
    Jin-Min Jung, In Ja Park, Eun Jung Park, Gyung Mo Son
    Annals of Surgical Treatment and Research.2023; 105(5): 252.     CrossRef
  • Recurrence Patterns and Risk Factors after Curative Resection for Colorectal Cancer: Insights for Postoperative Surveillance Strategies
    Hyo Seon Ryu, Jin Kim, Ye Ryung Park, Eun Hae Cho, Jeong Min Choo, Ji-Seon Kim, Se-Jin Baek, Jung-Myun Kwak
    Cancers.2023; 15(24): 5791.     CrossRef
  • Surgical safety in the COVID-19 era: present and future considerations
    Young Il Kim, In Ja Park
    Annals of Surgical Treatment and Research.2022; 102(6): 295.     CrossRef
  • Oncological outcomes of neoadjuvant chemotherapy in patients with resectable synchronous colorectal liver metastasis: A result from a propensity score matching study
    Yu-Juan Jiang, Si-Cheng Zhou, Jing-Hua Chen, Jian-Wei Liang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Molecular analyses of peritoneal metastasis from colorectal cancer
    Chang Hyun Kim
    Journal of the Korean Medical Association.2022; 65(9): 586.     CrossRef
  • Recent Advance in the Surgical Treatment of Metastatic Colorectal Cancer-An English Version
    Eun Jung Park, Seung Hyuk Baik
    Journal of the Anus, Rectum and Colon.2022; 6(4): 213.     CrossRef
  • Update on Diagnosis and Treatment of Colorectal Cancer
    Chan Wook Kim
    The Ewha Medical Journal.2022;[Epub]     CrossRef
  • Direction of diagnosis and treatment improvement in colorectal cancer
    In Ja Park
    Journal of the Korean Medical Association.2022; 65(9): 540.     CrossRef
  • Molecular Analyses in Peritoneal Metastasis from Colorectal Cancer: A Review-An English Version
    Chang Hyun Kim
    Journal of the Anus, Rectum and Colon.2022; 6(4): 197.     CrossRef
  • Surgical treatment for metastatic colorectal cancer
    Eun Jung Park, Seung Hyuk Baik
    Journal of the Korean Medical Association.2022; 65(9): 568.     CrossRef
  • Applications of propensity score matching: a case series of articles published in Annals of Coloproctology
    Hwa Jung Kim
    Annals of Coloproctology.2022; 38(6): 398.     CrossRef
Malignant disease, Prognosis and adjuvant therapy
Long-term Oncologic Outcome of Postoperative Complications After Colorectal Cancer Surgery
Chang Kyu Oh, Jung Wook Huh, You Jin Lee, Moon Suk Choi, Dae Hee Pyo, Sung Chul Lee, Seong Mun Park, Jung Kyong Shin, Yoon Ah Park, Yong Beom Cho, Seong Hyeon Yun, Hee Cheol Kim, Woo Yong Lee
Ann Coloproctol. 2020;36(4):273-280.   Published online November 13, 2019
DOI: https://doi.org/10.3393/ac.2019.10.15
  • 4,058 View
  • 162 Download
  • 16 Web of Science
  • 17 Citations
AbstractAbstract PDF
Purpose
The impact of postoperative complications on long-term oncologic outcome after radical colorectal cancer surgery is controversial. The aim of this study was to examine the risk factors and oncologic outcomes of surgery-related postoperative complication groups.
Methods
From January 2010 to December 2010, 310 patients experienced surgery-related postoperative complications after radical colorectal cancer surgery. These stage I–III patients were classified into 2 subgroups, minor (grades I, II) and major (grades III, IV) complication groups, according to extended Clavien-Dindo classification system criteria. Clinicopathologic differences between the 2 groups were analyzed to identify risk factors for major complications. The diseasefree survival rates of surgery-related postoperative complication groups were also compared.
Results
Minor and major complication groups were stratified with 194 patients (62.6%) and 116 patients (37.4%), respectively. The risk factors influencing the major complication group were pathologic N category and operative method. The prognostic factors associated with disease-free survival were preoperative perforation, perineural invasion, tumor budding, and receiving neoadjuvant therapy. With a median follow-up period of 72.2 months, the 5-year disease-free survival rates were 84.4% in the minor group and 78.5% in the major group, but there was no statistical significance between the minor and major groups (P = 0.392).
Conclusion
Advanced cancer and open surgery were identified as risk factors for increased surgery-related major complications after radical colorectal cancer surgery. However, severity of postoperative complications did not affect disease-free survival from colorectal cancer.

Citations

Citations to this article as recorded by  
  • Accelerated enhanced recovery after colon cancer surgery with discharge within one day after surgery: a systematic review
    Misha A. T. Sier, Anke H. C. Gielen, Thaís T. T. Tweed, Noémi C. van Nie, Tim Lubbers, Jan H. M. B. Stoot
    BMC Cancer.2024;[Epub]     CrossRef
  • Risk Factors of Postoperative Complication and Hospital Mortality after Colorectal Perforation Surgery
    Kensuke Kudou, Shuhei Kajiwara, Takashi Motomura, Takafumi Yukaya, Tomonori Nakanoko, Yosuke Kuroda, Masahiro Okamoto, Tadashi Koga, Yo-Ichi Yamashita
    Journal of the Anus, Rectum and Colon.2024; 8(2): 118.     CrossRef
  • Predictive value of POSSUM scoring system for postoperative complications and mortality in elderly patients with colorectal cancer
    Qiang Li, Yingjun Lu
    Technology and Health Care.2024; : 1.     CrossRef
  • Postoperative Complications Result in Poor Oncological Outcomes: What Is the Evidence?
    Anjana Wajekar, Sohan Lal Solanki, Juan Cata, Vijaya Gottumukkala
    Current Oncology.2024; 31(8): 4632.     CrossRef
  • Robotic versus Laparoscopic Total Mesorectal Excision Surgery in Rectal Cancer: Analysis of Medium-Term Oncological Outcomes
    Jing-jing Li, Zhi-bo Zhang, Shi-yun Xu, Cheng-ren Zhang, Xiong-fei Yang, Yao-xing Duan
    Surgical Innovation.2023; 30(1): 36.     CrossRef
  • Do postoperative infectious complications really affect long‐term survival in colorectal cancer surgery? A multicenter retrospective cohort study
    Akihisa Matsuda, Hiroshi Maruyama, Shinji Akagi, Toru Inoue, Kenichiro Uemura, Minako Kobayashi, Hisanori Shiomi, Manabu Watanabe, Hiroki Arai, Yutaka Kojima, Yusuke Mizuuchi, Hajime Yokomizo, Yuji Toiyama, Toru Miyake, Yasuyuki Yokoyama, Kei Ishimaru, Sh
    Annals of Gastroenterological Surgery.2023; 7(1): 110.     CrossRef
  • International Society of University Colon and Rectal Surgeons survey of surgeons’ preference on rectal cancer treatment
    Audrius Dulskas, Philip F. Caushaj, Domas Grigoravicius, Liu Zheng, Richard Fortunato, Joseph W. Nunoo-Mensah, Narimantas E. Samalavicius
    Annals of Coloproctology.2023; 39(4): 307.     CrossRef
  • Effect of serum lactate dehydrogenase-to-albumin ratio (LAR) on the short-term outcomes and long-term prognosis of colorectal cancer after radical surgery
    Xin-Peng Shu, Ying-Chun Xiang, Fei Liu, Yong Cheng, Wei Zhang, Dong Peng
    BMC Cancer.2023;[Epub]     CrossRef
  • Modified Clavien–Dindo–sink classification system for adolescent idiopathic scoliosis
    Ndéye F. Guissé, Joseph D. Stone, Lukas G. Keil, Tracey P. Bastrom, Mark A. Erickson, Burt Yaszay, Patrick J. Cahill, Stefan Parent, Peter G. Gabos, Peter O. Newton, Michael P. Glotzbecker, Michael P. Kelly, Joshua M. Pahys, Nicholas D. Fletcher
    Spine Deformity.2022; 10(1): 87.     CrossRef
  • Surgical site infection after laparoscopic resection of colorectal cancer is associated with compromised long-term oncological outcome
    Nana Sugamata, Takashi Okuyama, Emiko Takeshita, Haruka Oi, Yuhei Hakozaki, Shunya Miyazaki, Musashi Takada, Takashi Mitsui, Takuji Noro, Hideyuki Yoshitomi, Masatoshi Oya
    World Journal of Surgical Oncology.2022;[Epub]     CrossRef
  • Does Preoperative Waiting Time Affect the Short-Term Outcomes and Prognosis of Colorectal Cancer Patients? A Retrospective Study from the West of China
    Xiao-Yu Liu, Zi-Wei Li, Bing Kang, Yu-Xi Cheng, Wei Tao, Bin Zhang, Hua Zhang, Zheng-Qiang Wei, Dong Peng, Antonio Giovanni Solimando
    Canadian Journal of Gastroenterology and Hepatology.2022; 2022: 1.     CrossRef
  • Surgical safety in the COVID-19 era: present and future considerations
    Young Il Kim, In Ja Park
    Annals of Surgical Treatment and Research.2022; 102(6): 295.     CrossRef
  • Current status and role of robotic approach in patients with low-lying rectal cancer
    Hyo Seon Ryu, Jin Kim
    Annals of Surgical Treatment and Research.2022; 103(1): 1.     CrossRef
  • Robotic surgery for colorectal cancer
    Sung Uk Bae
    Journal of the Korean Medical Association.2022; 65(9): 577.     CrossRef
  • Low Anterior Resection Syndrome: Pathophysiology, Risk Factors, and Current Management
    Seung Mi Yeo, Gyung Mo Son
    The Ewha Medical Journal.2022;[Epub]     CrossRef
  • Current Status and Future of Robotic Surgery for Colorectal Cancer-An English Version
    Sung Uk Bae
    Journal of the Anus, Rectum and Colon.2022; 6(4): 221.     CrossRef
  • A propensity score-matched analysis of advanced energy devices and conventional monopolar device for colorectal cancer surgery: comparison of clinical and oncologic outcomes
    Woo Jin Song, Sung Uk Bae, Woon Kyung Jeong, Seong Kyu Baek
    Annals of Surgical Treatment and Research.2022; 103(5): 290.     CrossRef
Transanal Endoscopic and Transabdominal Robotic Total Mesorectal Excision for Mid-to-Low Rectal Cancer: Comparison of Short-term Postoperative and Oncologic Outcomes by Using a Case-Matched Analysis
Ki Young Lee, Jung Kyoung Shin, Yoon Ah Park, Seong Hyeon Yun, Jung Wook Huh, Yong Beom Cho, Hee Cheol Kim, Woo Yong Lee
Ann Coloproctol. 2018;34(1):29-35.   Published online February 28, 2018
DOI: https://doi.org/10.3393/ac.2018.34.1.29
  • 6,143 View
  • 109 Download
  • 21 Web of Science
  • 19 Citations
AbstractAbstract PDF
Purpose

This study aimed to compare short-term postoperative and oncologic outcomes of a transanal endoscopic total mesorectal excision (TME) to those of a transabdominal robotic TME.

Methods

A total of 62 patients with rectal cancer underwent transanal (n = 26) or robotic (n = 36) TME between June 2013 and December 2014. After case-matching by tumor location and TNM stage, 45 patients were included for analysis. The median follow-up period was 21.3 months. Operative, histopathologic and postoperative outcomes and recurrences were analyzed.

Results

Patients younger than 60 years of age were more frequently observed in the robotic TME group (75.0% vs. 47.6%, P = 0.059), but tumor location, cT and cN category, and preoperative chemoradiotherapy were not different between the 2 groups. Estimated blood loss was greater in the transanal group (283 mL vs. 155 mL, P = 0.061); however, the operation time and the rate of a diverting ileostomy and subsequent ileostomy repair were not different between the groups. The proximal resection margin was longer in the transanal TME group (20.8 cm ± 16.0 cm, P = 0.030), but the distal resection margins, involvements of the circumferential resection margin, TME quality, numbers of retrieved lymph nodes, postoperative complications, including anastomotic leak and voiding difficulty, and recurrence rates for the 2 groups were not statistically different.

Conclusion

Transanal endoscopic and transabdominal robotic TME showed similar histopathologic and postoperative outcomes with the exception of the estimated blood loss and the proximal resection margin for a select group of patients.

Citations

Citations to this article as recorded by  
  • Peri-operative, oncological and functional outcomes of robotic versus transanal total mesorectal excision in patients with rectal cancer: A systematic review and meta-analysis
    A. Y. Y. Mohamedahmed, S. Zaman, A. A. Wuheb, A. Ismail, M. Nnaji, A. A. Alyamani, H. A. Eltyeb, N. A. Yassin
    Techniques in Coloproctology.2024;[Epub]     CrossRef
  • Systematic review and meta-analysis comparing robotic total mesorectal excision versus transanal total mesorectal excision for rectal cancer
    Mohamed Ali Chaouch, Mohammad Iqbal Hussain, Maissa Jellali, Amine Gouader, Alessandro Mazzotta, Adriano Carneiro da Costa, Bassem Krimi, Jim Khan, Hani Oweira
    Scandinavian Journal of Surgery.2024;[Epub]     CrossRef
  • A systematic review and meta-analysis of minimally invasive total mesorectal excision versus transanal total mesorectal excision for mid and low rectal cancer
    Du Yong Gang, Lin Dong, Zhang DeChun, Zhang Yichi, Lu Ya
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Robotic-assisted laparoscopic low anterior resection versus trans-anal total mesorectal excision for malignant rectal lesion: a prospective cohort trial
    Ahmed F.A. Farag, Ahmed M.A. Mahmoud, Haitham M. Azmy, Abdrabbou N. Mashhour, Ahmed S. Khalifa, Yasser Debakey, Mohamed Y. Elbarmelgi
    The Egyptian Journal of Surgery.2023; 42(4): 859.     CrossRef
  • Robotic or transanal total mesorectal excision (TaTME) approach for rectal cancer, how about both? Feasibility and outcomes from a single institution
    Yusuke Inoue, Jing Yu Ng, Chun-Ho Chu, Yi-Ling Lai, I.-Ping Huang, Shung-Haur Yang, Chien-Chih Chen
    Journal of Robotic Surgery.2022; 16(1): 149.     CrossRef
  • Long-term oncologic outcomes of transanal TME compared with transabdominal TME for rectal cancer: a systematic review and meta-analysis
    Jae Young Moon, Min Ro Lee, Gi Won Ha
    Surgical Endoscopy.2022; 36(5): 3122.     CrossRef
  • Multidisciplinary treatment strategy for early rectal cancer
    Gyung Mo Son, In Young Lee, Sung Hwan Cho, Byung-Soo Park, Hyun Sung Kim, Su Bum Park, Hyung Wook Kim, Sang Bo Oh, Tae Un Kim, Dong Hoon Shin
    Precision and Future Medicine.2022; 6(1): 32.     CrossRef
  • Comparison of transanal total mesorectal excision and robotic total mesorectal excision for low rectal cancer after neoadjuvant chemoradiotherapy
    Jung Kyong Shin, Hee Cheol Kim, Seong Hyeon Yun, Yoon Ah Park, Yong Beom Cho, Jung Wook Huh, Woo Yong Lee
    Surgical Endoscopy.2021; 35(12): 6998.     CrossRef
  • Statistical, Clinical, Methodological Evaluation of Local Recurrence Following Transanal Total Mesorectal Excision for Rectal Cancer: A Systematic Review
    Hans H. Wasmuth, Mahir Gachabayov, Les Bokey, Abe Fingerhut, Guy R. Orangio, Feza H. Remzi, Roberto Bergamaschi
    Diseases of the Colon & Rectum.2021; 64(7): 899.     CrossRef
  • A nationwide comparison of short‐term outcomes after transanal, open, laparoscopic, and robot‐assisted total mesorectal excision
    Ilze Ose, Sharaf Karim Perdawood
    Colorectal Disease.2021; 23(10): 2671.     CrossRef
  • Robotic total mesorectal excision or transanal total mesorectal excision meta‐analysis
    Michelle Zhiyun Chen, Yeng Kwang Tay, Satish K. Warrier, Alexander G. Heriot, Joseph C. Kong
    ANZ Journal of Surgery.2021; 91(11): 2269.     CrossRef
  • A systematic review and meta-analysis of robotic-assisted transabdominal total mesorectal excision and transanal total mesorectal excision: which approach offers optimal short-term outcomes for mid-to-low rectal adenocarcinoma?
    J. W. Butterworth, W. A. Butterworth, J. Meyer, C. Giacobino, N. Buchs, F. Ris, R. Scarpinata
    Techniques in Coloproctology.2021; 25(11): 1183.     CrossRef
  • Outcomes of robotic low anterior resection versus transanal total mesorectal excision for rectal cancer
    J L B Buan, W Z So, X C Lim, C S Chong
    BJS Open.2021;[Epub]     CrossRef
  • Initial Experience of Robotic Total Mesorectal Excision for Rectal Cancer
    Jung Kyong Shin, Jung Wook Huh
    Annals of Robotic and Innovative Surgery.2020; 1(1): 33.     CrossRef
  • Robotic Total Mesorectal Excision for Rectal Cancer: Current Evidences and Future Perspectives
    Je-Ho Jang, Chang-Nam Kim
    Annals of Coloproctology.2020; 36(5): 293.     CrossRef
  • Systemic review and network meta‐analysis comparing minimal surgical techniques for rectal cancer: quality of total mesorectum excision, pathological, surgical, and oncological outcomes
    Emanuele Rausa, Federica Bianco, Michael E. Kelly, Alberto Aiolfi, Fausto Petrelli, Gianluca Bonitta, Giovanni Sgroi
    Journal of Surgical Oncology.2019; 119(7): 987.     CrossRef
  • Does transanal total mesorectal excision of rectal cancer improve histopathology metrics and/or complication rates? A meta-analysis
    Mahir Gachabayov, Inna Tulina, Roberto Bergamaschi, Petr Tsarkov
    Surgical Oncology.2019; 30: 47.     CrossRef
  • Transanal Total Mesorectal Excision for Rectal Cancer: Perioperative and Oncological Outcomes
    Hyuk Hur
    Annals of Coloproctology.2018; 34(1): 1.     CrossRef
  • Evolution of surgery for rectal cancer: Transanal total mesorectal excision~new standard or fad?~
    Hirotoshi Hasegawa, Koji Okabayashi, Masashi Tsuruta, Takashi Ishida, Fumitaka Asahara, Mark G Coleman
    Journal of the Anus, Rectum and Colon.2018; 2(4): 115.     CrossRef
Clinical Significance of Signet-Ring-Cell Colorectal Cancer as a Prognostic Factor
Sang-Oh Yun, Yong Beom Cho, Woo Yong Lee, Hee Cheol Kim, Seong Hyeon Yun, Yoon Ah Park, Jung Wook Huh
Ann Coloproctol. 2017;33(6):232-238.   Published online December 31, 2017
DOI: https://doi.org/10.3393/ac.2017.33.6.232
  • 4,917 View
  • 47 Download
  • 26 Web of Science
  • 25 Citations
AbstractAbstract PDF
Purpose

The aim of this study is to evaluate the prognosis for patients with a signet-ring-cell carcinoma (SRCC) who undergo curative surgery by comparing them to patients with an adenocarcinoma (ADC), excluding a mucinous ADC.

Methods

Between September 1994 and December 2013, 14,110 patients with colorectal cancer underwent surgery and among them, 12,631 patients were enrolled in this study. 71 patients with a SRCC and 12,570 patients with a ADC were identified. We analyzed the disease-free survival and the overall survival rates before and after a 1:2 propensity score matching and evaluated those rates after stage stratification.

Results

The median follow-up durations were 48.5 months for the SRC group and 48.6 months for the ADC group. The disease-free survival rates and the overall survival rates were significantly lower in the SRC group before and after propensity score matching (P < 0.001). After stratification by stage, no differences were observed between the SRC and the ADC groups for the disease-free survival (DFS) and the overall survival (OS) rates for patients with cancer in its early stages (P = 0.913 and P = 0.380 for the DFS and the OS, respectively, in stages 0 and I, and P = 0.223 and P = 0.991 for the DFS and the OS, respectively, in stage II), but those rates were significantly lower in the SRC group for cancer in its later stages (P < 0.001, respectively in stages III and IV).

Conclusion

For cancer in advanced stages, patients with a resectable colorectal SRCC had a poorer prognosis after propensity score matching than those with an ADC did. Therefore, more intensive surveillance and closer observation should be offered to such patients.

Citations

Citations to this article as recorded by  
  • Prognostic implications of T stage in different pathological types of colorectal cancer: an observational study using SEER population-based data
    Nan Yao, Wenqiang Li, Jiwei Wang, Hongyuan Chu, Ning Duan, Xinyu Niu, Guoyong Yu, Jun Qu
    BMJ Open.2024; 14(2): e076579.     CrossRef
  • Systematic review of risk factors, prognosis, and management of colorectal signet-ring cell carcinoma
    Frederiek Nuytens, Vincent Drubay, Clarisse Eveno, Florence Renaud, Guillaume Piessen
    World Journal of Gastrointestinal Oncology.2024; 16(5): 2141.     CrossRef
  • Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patient
    Erica Torchiaro, Consalvo Petti, Sabrina Arena, Francesco Sassi, Giorgia Migliardi, Alfredo Mellano, Roberta Porporato, Marco Basiricò, Loretta Gammaitoni, Enrico Berrino, Monica Montone, Giorgio Corti, Giovanni Crisafulli, Caterina Marchiò, Alberto Barde
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Prognosis of Different Histological Types in Patients with Stage II and III Colon Cancer
    Yasmeen Z. Qwaider, Naomi M. Sell, Caitlin E. Stafford, Chloe Boudreau, Hiroko Kunitake, Robert N. Goldstone, Rocco Ricciardi, Liliana G. Bordeianou, Christy E. Cauley, David L. Berger
    Journal of Gastrointestinal Surgery.2022; 26(2): 476.     CrossRef
  • Tumor budding as a prognostic indicator in colorectal carcinoma: a retrospective study of primary colorectal carcinoma cases in a tertiary care center
    Ashini H. Shah, Amisha J. Gami, Neetal H. Desai, Jahnavi S. Gandhi, Priti P. Trivedi
    Indian Journal of Surgical Oncology.2022; 13(3): 459.     CrossRef
  • The Association of Microbiome Dysbiosis With Colorectal Cancer
    Artem Artemev, Sheetal Naik, Anastasia Pougno, Prasanna Honnavar, Nandan M Shanbhag
    Cureus.2022;[Epub]     CrossRef
  • Simple synthesis of WO3 based activated carbon co-doped CuS composites for photocatalytic applications
    Tahir Iqbal, Maria Ashraf, Arslan Masood
    Inorganic Chemistry Communications.2022; 139: 109322.     CrossRef
  • Predictors of Long-Time Survivors in Nonmetastatic Colorectal Signet Ring Cell Carcinoma: A Large Population-Based Study
    Wuguang Zhang, Wenqian Gong, Changhai Wu, Mengting Li, Xiaolong Tu, Stephen Fink
    Gastroenterology Research and Practice.2022; 2022: 1.     CrossRef
  • Applications of propensity score matching: a case series of articles published in Annals of Coloproctology
    Hwa Jung Kim
    Annals of Coloproctology.2022; 38(6): 398.     CrossRef
  • Does signet ring cell carcinoma component signify worse outcomes for patients with colorectal cancer?
    Liming Wang, Yasumitsu Hirano, Gregory Heng, Toshimasa Ishii, Hiroka Kondo, Kiyoka Hara, Nao Obara, Masahiro Asari, Takuya Kato, Shigeki Yamaguchi
    Asian Journal of Surgery.2021; 44(1): 105.     CrossRef
  • The Impact of Histologic Subtype on Receipt of Adjuvant Chemotherapy and Overall Survival in Stage III Colon Cancer: a Retrospective Cohort Analysis
    Benjamin D. Powers, Seth I. Felder, Iman Imanirad, Sophie Dessureault, Sean P. Dineen
    Journal of Gastrointestinal Cancer.2021; 52(2): 719.     CrossRef
  • Colorectal adenocarcinomas diagnosed following a negative faecal immunochemical test show high‐risk pathological features in a colon screening programme
    Michael J. Steel, Hussam Bukhari, Laura Gentile, Jennifer Telford, David F. Schaeffer
    Histopathology.2021; 78(5): 710.     CrossRef
  • Colorectal cancer of the young displays distinct features of aggressive tumor biology: A single-center cohort study
    Matteo Mueller, Marcel André Schneider, Barla Deplazes, Daniela Cabalzar-Wondberg, Andreas Rickenbacher, Matthias Turina
    World Journal of Gastrointestinal Surgery.2021; 13(2): 164.     CrossRef
  • Clinicopathological factors and survival outcomes of signet-ring cell and mucinous carcinoma versus adenocarcinoma of the colon and rectum: a systematic review and meta-analysis
    Michael G. Fadel, George Malietzis, Vasilis Constantinides, Gianluca Pellino, Paris Tekkis, Christos Kontovounisios
    Discover Oncology.2021;[Epub]     CrossRef
  • MRI features of signet ring rectal cancer
    Meena Suthar, Akshay D. Baheti, Suman K. Ankathi, Amit Choudhari, Purvi D. Haria, Reena Engineer, Vikas Ostwal, Mukta S. Ramadwar, Ashwin Desouza, Avanish Saklani
    Abdominal Radiology.2021; 46(12): 5536.     CrossRef
  • Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population‐based analysis
    Jiwei Wang, Song Li, Yanna Liu, Chunquan Zhang, Honglang Li, Bin Lai
    Cancer Medicine.2020; 9(1): 361.     CrossRef
  • Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta‐analysis
    V. Narasimhan, S. Tan, J. Kong, T. Pham, M. Michael, R. Ramsay, S. Warrier, A. Heriot
    Colorectal Disease.2020; 22(11): 1482.     CrossRef
  • Deconvolution of diffuse gastric cancer and the suppression of CD34 on the BALB/c nude mice model
    Seon-Jin Yoon, Jungmin Park, Youngmin Shin, Yuna Choi, Sahng Wook Park, Seok-Gu Kang, Hye Young Son, Yong-Min Huh
    BMC Cancer.2020;[Epub]     CrossRef
  • Predictive factors of complete pathological response in patients with locally advanced rectal cancer
    Rebekah M. Engel, Karen Oliva, Christine Koulis, Raymond Yap, Paul J. McMurrick
    International Journal of Colorectal Disease.2020; 35(9): 1759.     CrossRef
  • Clinicopathological Characteristics and Mutation Spectrum of Colorectal Adenocarcinoma With Mucinous Component in a Chinese Cohort: Comparison With Classical Adenocarcinoma
    Jingci Chen, Liangrui Zhou, Jie Gao, Tao Lu, Jing Wang, Huanwen Wu, Zhiyong Liang
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Signet ring cell component in pretreatment biopsy predicts pathological response to preoperative chemoradiotherapy in rectal cancer
    Xue Chao, Zixian Wang, Shixun Lu, Yuhua Huang, Shengbing Zang, Peirong Ding, Huizhong Zhang, Jingping Yun
    International Journal of Clinical Oncology.2020; 25(9): 1653.     CrossRef
  • Laparoscopic Surgery for Colorectal Cancer in Korea: Nationwide Data from 2013 to 2018
    Sun Jin Park, Kil Yeon Lee, Suk-Hwan Lee
    Cancer Research and Treatment.2020; 52(3): 938.     CrossRef
  • Outcomes of Definitive Treatment of Signet Ring Cell Carcinoma of the Rectum: Is Minimal Invasive Surgery Detrimental in Signet Ring Rectal Cancers?
    S. Raghavan, Deepak Kumar Singh, J. Rohila, A. DeSouza, R. Engineer, A. Ramaswamy, V. Ostwal, A. Saklani
    Indian Journal of Surgical Oncology.2020; 11(4): 597.     CrossRef
  • Aggressive Colorectal Cancer in the Young
    Blake Read, Patricia Sylla
    Clinics in Colon and Rectal Surgery.2020; 33(05): 298.     CrossRef
  • Prognoses of different pathological subtypes of colorectal cancer at different stages: A population-based retrospective cohort study
    Xiaoli Wu, Han Lin, Shaotang Li
    BMC Gastroenterology.2019;[Epub]     CrossRef
Oncologic Outcomes of Stage IIIA Colon Cancer for Different Chemotherapeutic Regimens
Yoo Sung Lee, Hee Cheol Kim, Kyung Ook Jung, Yong Beom Cho, Seong Hyeon Yun, Woo Yong Lee, Ho-Kyung Chun
J Korean Soc Coloproctol. 2012;28(5):259-264.   Published online October 31, 2012
DOI: https://doi.org/10.3393/jksc.2012.28.5.259
  • 3,759 View
  • 12 Download
  • 2 Citations
AbstractAbstract PDF
Purpose

Adjuvant chemotherapy is currently recommended for Stage IIIA colon cancers. This study aimed to elucidate the oncologic outcomes of Stage IIIA colon cancer according to the chemotherapeutic regimen based on a retrospective review.

Methods

From 1995 to 2008, Stage IIIA colon cancer patients were identified from a prospectively maintained database at a single institution. Exclusion criteria were as follows: rectal cancer, another malignancy other than colon cancer, no adjuvant chemotherapy and unknown chemotherapeutic regimen. One hundred thirty-one patients were enrolled in the study, and the clinicopathologic and the oncologic characteristics were analyzed. The number of males was 72, and the number of females was 59; the mean age was 59.5 years (range, 25 to 76 years), and the median follow-up period was 33 months (range, 2 to 127 months).

Results

Of the 131 patients, fluorouracil/leucovorin (FL)/capecitabine chemotherapy was performed in 109 patients, and FOLFOX chemotherapy was performed in 22 patients. When the patients who received FL/capecitabine chemotherapy and the patients who received FOLFOX chemotherapy were compared, there was no significant difference in the clinicopathologic factors between the two groups. The 5-year overall survival and the 5-year disease-free survival were 97.2% and 94.5% in the FL/capecitabine patient group and 95.5% and 90.9% in the FOLFOX patient group, respectively, and no statistically significant differences were noted between the two groups.

Conclusion

Stage IIIA colon cancer showed good oncologic outcomes, and the chemotherapeutic regimen did not seem to affect the oncologic outcome.

Citations

Citations to this article as recorded by  
  • A New Method for Constructing Macrophage-Associated Predictors of Treatment Efficacy Based on Single-Cell Sequencing Analysis
    Jianxiu Lin, Yang Ran, Tengfei Wu, Zishan Wang, Jinjin Zhao, Yun Tian
    Journal of Immunotherapy.2024; 47(2): 33.     CrossRef
  • Distinctive oncological features of stage IIIA colorectal cancer: Analysis of prognostic factors for selective adjuvant chemotherapy
    Soo Yeun Park, Gyu‐Seog Choi, Jun Seok Park, Hye Jin Kim, Yoshiharu Sakai, Suguru Hasegawa, Toshiaki Watanabe, Seon Hahn Kim
    Journal of Surgical Oncology.2015; 111(7): 882.     CrossRef
Transanal Endoscopic Microsurgery for the Treatment of Well-Differentiated Rectal Neuroendocrine Tumors
Hyoung Ran Kim, Woo Yong Lee, Kyung Uk Jung, Hyuk Jun Chung, Chul Joong Kim, Hae-Ran Yun, Yong Beom Cho, Seong Hyeon Yun, Hee Cheol Kim, Ho-Kyung Chun
J Korean Soc Coloproctol. 2012;28(4):201-204.   Published online August 31, 2012
DOI: https://doi.org/10.3393/jksc.2012.28.4.201
  • 3,996 View
  • 30 Download
  • 8 Citations
AbstractAbstract PDF
Purpose

Recently, an increase in well-differentiated rectal neuroendocrine tumors (WRNETs) has been noted. We aimed to evaluate transanal endoscopic microsurgery (TEM) for the treatment of WRNETs.

Methods

Between December 1995 and August 2009, 109 patients with WRNETs underwent TEM. TEM was performed for patients with tumors sizes of up to 20 mm and without a lymphadenopathy. These patients had been referred from other clinics after having been diagnosed with WRNETs by using a colonoscopic biopsy; they had undergone a failed endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR) and exhibited an involved resection margin and remaining tumor after ESD or EMR, regardless of the distance from the anal verge. This study included 38 patients that had more than three years of follow-up.

Results

The mean age of the patients was 51.3 ± 11.9 years, the mean tumor size was 8.0 ± 3.9 mm, and no morbidity occurred. Thirty-five patients were asymptomatic. TEM was performed after a colonoscopic resection in 13 cases because of a positive resection margin, a residual tumor or a non-lifting lesion. Complete resections were performed in 37 patients; one patient with a positive margin was considered surgically complete. In one patient, liver metastasis and a recurrent mesorectal node occurred after five and 10 years, respectively.

Conclusion

TEM might provide an accessible and effective treatment either as an initial or as an adjunct after a colonoscopic resection for a WRNET.

Citations

Citations to this article as recorded by  
  • Oncological outcomes according to the treatment modality based on the size of rectal neuroendocrine tumors: a single-center retrospective study
    Jimin Son, In Ja Park, Dong-Hoon Yang, Jisup Kim, Kyoung-Jo Kim, Jeong-Sik Byeon, Seung Mo Hong, Young Il Kim, Jong Beom Kim, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim
    Surgical Endoscopy.2022; 36(4): 2445.     CrossRef
  • Long-term outcomes of transanal endoscopic microsurgery for the treatment of rectal neuroendocrine tumors
    Wei-Kun Shi, Rui Hou, Yun-Hao Li, Xiao-Yuan Qiu, Yu-Xin Liu, Bin Wu, Yi Xiao, Jiao-Lin Zhou, Guo-Le Lin
    BMC Surgery.2022;[Epub]     CrossRef
  • Non-conventional applications for transanal endoscopic microsurgery. A single center experience and a systematic review of literature
    Rosita DE VINCENTI, Fabio CIANCHI, Francesco CORATTI
    Minerva Surgery.2022;[Epub]     CrossRef
  • Transanalis műtéti útmutató – második kiadás
    Kálmán Almási, Szabolcs Ábrahám, József Baracs, Attila Bursics, Zoltán Jánó, Tamás Sztipits, Áron Szűts, Dezső Tóth, Attila Zaránd, Balázs Bánky
    Orvosi Hetilap.2022; 163(Supplement): 3.     CrossRef
  • Endoscopic submucosal dissection versus transanal local excision for rectal carcinoid: a comparative study
    Fei-hu Yan, Zheng Lou, Shi-jie Hu, Xiao-dong Xu, Hao Wang, Han-tao Wang, Rong-gui Meng, Chuan-gang Fu, Wei Zhang, Jian He, En-da Yu
    World Journal of Surgical Oncology.2016;[Epub]     CrossRef
  • Efficacy and Safety of Endoscopic Resection Therapies for Rectal Carcinoid Tumors: A Meta-Analysis
    Lei He, Tao Deng, Hesheng Luo
    Yonsei Medical Journal.2015; 56(1): 72.     CrossRef
  • Full-thickness excision using transanal endoscopic microsurgery for treatment of rectal neuroendocrine tumors
    Wei-Jie Chen
    World Journal of Gastroenterology.2015; 21(30): 9142.     CrossRef
  • Current Issues Involving the Treatment of Small Rectal Carcinoid Tumors
    Dae Kyung Sohn
    Journal of the Korean Society of Coloproctology.2012; 28(4): 176.     CrossRef
Risk Factors for Repeat Abdominal Surgery in Korean Patients with Crohn's Disease: A Multi-Center Study of a Korean Inflammatory Bowel Disease Study Group
Kil Yeon Lee, Chang Sik Yu, Kang Young Lee, Yong Beom Cho, Kyu Joo Park, Gyu-Seog Choi, Sang Nam Yoon, Hanna Yoo
J Korean Soc Coloproctol. 2012;28(4):188-194.   Published online August 31, 2012
DOI: https://doi.org/10.3393/jksc.2012.28.4.188
  • 3,112 View
  • 24 Download
  • 8 Citations
AbstractAbstract PDF
Purpose

The purpose of this study was to assess the risk factors for repeated abdominal surgery in Crohn's disease (CD) patients after the first abdominal surgery. Prior studies have tried to identify the risk factors for postoperative recurrence in CD patients, but the results of the studies have been inconsistent. Furthermore, few data on the risk factors for repeated abdominal surgery are available.

Methods

Clinical data on CD patients who underwent abdominal surgery from January 2000 to December 2009 were collected from seventeen university hospitals and one colorectal clinic. Data from a total of 708 patients were analyzed to find the risk factors for repeated abdominal surgery in CD patients. The mean follow-up period was 72 months.

Results

The risk of repeated abdominal surgery was 3 times higher in young patients (below 16 years old) than in older patients (odds ratio [OR], 3.056; 95% confidence interval [CI], 1.021 to 9.150); P = 0.046). Stricturing behavior at diagnosis was also a risk factor for repeated abdominal surgery (OR, 2.438; 95% CI, 1.144 to 5.196; P = 0.021). Among operative indications, only intra-abdominal abscess was associated with repeated abdominal surgery (OR, 2.393; 95% CI, 1.098 to 5.216; P = 0.028). Concerning type of operation, an ileostomy might be a risk factor for repeated abdominal surgery (OR, 11.437; 95% CI, 1.451 to 90.124; P = 0.021). Emergency surgery (OR, 4.994; 95% CI, 2.123 to 11.745; P < 0.001) and delayed diagnosis after surgery (OR, 2.339; 95% CI, 1.147 to 4.771; P = 0.019) also increased the risk of repeated abdominal surgery.

Conclusion

Young age (below 16 years), stricturing behavior, intra-abdominal abscess, emergency surgery, and delayed diagnosis after surgery were identified as possible risk factors for repeated abdominal surgery in CD patients.

Citations

Citations to this article as recorded by  
  • Therapeutic strategies in Crohn’s disease in an emergency surgical setting
    Maria Michela Chiarello, Gilda Pepe, Valeria Fico, Valentina Bianchi, Giuseppe Tropeano, Gaia Altieri, Giuseppe Brisinda
    World Journal of Gastroenterology.2022; 28(18): 1902.     CrossRef
  • Risk Factors for Postoperative Recurrence in Korean Patients with Crohn’s Disease
    Sung Bae Kim, Jae Hee Cheon, Jae Jun Park, Eun Soo Kim, Seong Woo Jeon, Sung-Ae Jung, Dong Il Park, Chang Kyun Lee, Jong Pil Im, You Sun Kim, Hyun Soo Kim, Jun Lee, Chang Soo Eun, Jeong Mi Lee, Byung Ik Jang, Geom Seog Seo
    Gut and Liver.2020; 14(3): 331.     CrossRef
  • Prevalence and factors associated with re-laparotomy among patients operated in Debre-Markos referral hospital, north west Ethiopia: Retrospective cross-sectional study
    Yeneabat Birhanu, Debrework Tesgera, Henok Biresaw Netsere, Nurhusien Nuru
    International Journal of Africa Nursing Sciences.2020; 13: 100249.     CrossRef
  • Comparison of missing data methods in clustered survival data using Bayesian adaptive B-Spline estimation
    Hanna Yoo, Jae Won Lee
    Communications for Statistical Applications and Methods.2018; 25(2): 159.     CrossRef
  • Patients with perianal Crohn's disease have poor disease outcomes after primary bowel resection
    Yoo Min Han, Ji Won Kim, Seong‐Joon Koh, Byeong Gwan Kim, Kook Lae Lee, Jong Pil Im, Joo Sung Kim, Hyun Chae Jung
    Journal of Gastroenterology and Hepatology.2016; 31(8): 1436.     CrossRef
  • The Clinical Features and Predictive Risk Factors for Reoperation in Patients With Perianal Crohn Diseases; A Multi-Center Study of a Korean Inflammatory Bowel Disease Study Group
    Jae Bum Lee, Seo-Gue Yoon, Kyu Joo Park, Kang Young Lee, Dae Dong Kim, Sang Nam Yoon, Chang Sik Yu
    Annals of Coloproctology.2015; 31(5): 176.     CrossRef
  • Crohn's disease in Korea: past, present, and future
    Kang-Moon Lee, Ji Min Lee
    The Korean Journal of Internal Medicine.2014; 29(5): 558.     CrossRef
  • Clinical and Endoscopic Recurrence after Surgical Resection in Patients with Crohn's Disease
    Yang Woon Lee, Kang-Moon Lee, Woo Chul Chung, Chang Nyol Paik, Hea Jung Sung, You Suk Oh
    Intestinal Research.2014; 12(2): 117.     CrossRef
Treatment Outcomes of Anorectal Melanoma
Byung Min Choi, Hyoung Ran Kim, Hae-Ran Yun, Seung Ho Choi, Yong Beom Cho, Hee Cheol Kim, Seong Hyeon Yun, Woo Yong Lee, Ho-Kyung Chun
J Korean Soc Coloproctol. 2011;27(1):27-30.   Published online February 28, 2011
DOI: https://doi.org/10.3393/jksc.2011.27.1.27
  • 3,251 View
  • 40 Download
  • 18 Citations
AbstractAbstract PDF
Purpose

An anorectal melanoma (AM) is a very rare tumor. However, sufficient data supporting effective surgical options for the disease do not exist. This retrospective review aimed to analyze treatment outcomes for an AM.

Methods

From June 1999 to December 2008, we retrospectively reviewed a prospectively collected consecutive series of 19 patients who had undergone a surgical resection for an AM at a single institute. Surgical method and clinicopathological factors were analyzed.

Results

The median age was 61.4 years (range, 46 to79 years). Main symptoms were an anal mass, hematochezia, perianal pain, tenesmus, fecal incontinence, and bowel habit change. The average duration of symptoms before diagnosis was 7.8 months (range, 1 to 36 months). S-100 and HMB-45 were positive in all patients, even in non-melanin pigmentation. There were 12 abdominoperineal resections (APRs) and 7 wide local excisions (WEs). The APR showed longer overall survival when compared with the WE (64.1 months vs. 10.9 months, P < 0.001). No patients who underwent a WE survived more than 13 months.

Conclusion

A high index of suspicion is necessary to establish the diagnosis for an AM in patients with anal symptoms, and S-100 and HMB-45 can be useful markers for an AM. Even with the small number of cases and the short follow-up, our data suggest that an APR for an AM may provide longer survival than a WE.

Citations

Citations to this article as recorded by  
  • Optimal surgical management strategy for treatment of primary anorectal malignant melanoma—a systematic review and meta-analysis
    Hugo C. Temperley, Niall J. O’Sullivan, Alan Keyes, Dara O. Kavanagh, John O. Larkin, Brian J. Mehigan, Paul H. McCormick, Michael E. Kelly
    Langenbeck's Archives of Surgery.2022; 407(8): 3193.     CrossRef
  • Trends in the management of anorectal melanoma: A multi-institutional retrospective study and review of the world literature
    Josh Bleicher, Jessica N Cohan, Lyen C Huang, William Peche, T Bartley Pickron, Courtney L Scaife, Tawnya L Bowles, John R Hyngstrom, Elliot A Asare
    World Journal of Gastroenterology.2021; 27(3): 267.     CrossRef
  • Survival following surgical treatment for anorectal melanoma seems similar for local excision and extensive resection regardless of nodal involvement
    E. Jutten, S. Kruijff, A.B. Francken, H.L. van Westreenen, K.P. Wevers
    Surgical Oncology.2021; 37: 101558.     CrossRef
  • Response to Kahlke et al
    Audrius Dulskas
    Colorectal Disease.2021; 23(11): 3029.     CrossRef
  • Three Cases of Anorectal Malignant Melanoma Treated with Laparoscopic Abdominoperineal Resection
    Shin Yoshida, Nobuaki Suzuki, Shinobu Tomochika, Yoshitaro Shindo, Yukio Tokumitsu, Michihisa Iida, Shigeru Takeda, Tatsuya Ioka, Shoichi Hazama, Tsuzuri Shirahama, Hiroo Kawano, Eiji Ikeda, Hiroaki Nagano
    The Japanese Journal of Gastroenterological Surgery.2021; 54(9): 644.     CrossRef
  • Spectrum of presentation in primary anorectal malignant melanoma and its management
    Barun Kumar Singh, Samrat Ray, Shashi Dhawan, Samiran Nundy
    BMJ Case Reports.2021; 14(10): e245449.     CrossRef
  • Surgical treatment of anorectal melanoma: a systematic review and meta-analysis
    Esther Jutten, Schelto Kruijff, Anne Brecht Francken, Martijn F Lutke Holzik, Barbara L van Leeuwen, Henderik L van Westreenen, Kevin P Wevers
    BJS Open.2021;[Epub]     CrossRef
  • Long-term Oncologic Outcome and Its Relevant Factors in Anal Cancer in Korea: A Nationwide Data Analysis
    Hyuk Hur, Kyu-Won Jung, Byung-Woo Kim, Chang-Mo Oh, Young-Joo Won, Jae Hwan Oh, Nam Kyu Kim
    Annals of Coloproctology.2020; 36(1): 35.     CrossRef
  • Primary anorectal malignant melanoma with laparoscopic abdominoperineal resection: a case study and review of the relevant literature
    Kentaro Nonaka, Kensuke Kudou, Shun Sasaki, Tomoko Jogo, Kosuke Hirose, Yuta Kasagi, Qingjiang Hu, Yasuo Tsuda, Yuichi Hisamatsu, Koji Ando, Yuichiro Nakashima, Hiroshi Saeki, Eiji Oki, Mitsuo Kamori, Masaki Mori
    International Cancer Conference Journal.2020; 9(3): 116.     CrossRef
  • Less is more: A systematic review and meta-analysis of the outcomes of radical versus conservative primary resection in anorectal melanoma
    Henry G. Smith, Jessica Glen, Nancy Turnbull, Howard Peach, Ruth Board, Miranda Payne, Martin Gore, Karen Nugent, Myles J.F. Smith
    European Journal of Cancer.2020; 135: 113.     CrossRef
  • Anorectal Malignant Melanoma: Retrospective Analysis of Six Patients and Review of the Literature
    Ibrahim Atak
    Prague Medical Report.2018; 119(2-3): 97.     CrossRef
  • Extensive surgery and lymphadenectomy do not improve survival in primary melanoma of the anorectum: results from analysis of a large database (SEER)
    A. Ciarrocchi, R. Pietroletti, F. Carlei, G. Amicucci
    Colorectal Disease.2017; 19(2): 158.     CrossRef
  • Das anorektale maligne Melanom
    T. R. Glowka, M. D. Keyver-Paik, T. Thiesler, J. Landsberg, J. C. Kalff, D. Pantelis
    Der Chirurg.2016; 87(9): 768.     CrossRef
  • Abdominoperineal Resection Provides Better Local Control But Equivalent Overall Survival to Local Excision of Anorectal Malignant Melanoma
    Akihisa Matsuda, Masao Miyashita, Satoshi Matsumoto, Goro Takahashi, Takeshi Matsutani, Takeshi Yamada, Taro Kishi, Eiji Uchida
    Annals of Surgery.2015; 261(4): 670.     CrossRef
  • Anorectal malignant melanoma: retrospective analysis of management and outcome in a single Portuguese Institution
    Isália Miguel, João Freire, Maria José Passos, António Moreira
    Medical Oncology.2015;[Epub]     CrossRef
  • Characteristics and Survival of Korean Anal Cancer From the Korea Central Cancer Registry Data
    Hyoung-Chul Park, Kyu-Won Jung, Byung-Woo Kim, Aesun Shin, Young-Joo Won, Jae Hwan Oh, Seung-Yong Jeong, Chang Sik Yu, Bong Hwa Lee
    Annals of Coloproctology.2013; 29(5): 182.     CrossRef
  • Incidence and Survival Patterns of Rare Anal Canal Neoplasms Using the Surveillance Epidemiology and End Results Registry
    Cristina Metildi, Elisabeth C. McLemore, Thuy Tran, David Chang, Bard Cosman, Sonia L. Ramamoorthy, Sidney L. Saltzstein, Georgia Robins Sadler
    The American Surgeon.2013; 79(10): 1068.     CrossRef
  • Rectal melanoma
    N. Patelis, P. Marselos, G. Sotiropoulou, S. Georgiou, A. Kominea
    Hellenic Journal of Surgery.2012; 84(3): 198.     CrossRef
Oncologic Outcome after Cessation or Dose Reduction of Capecitabine in Patients with Colon Cancer
Jung-A Yun, Hee Cheol Kim, Hyun-Sook Son, Hyoung Ran Kim, Hae Ran Yun, Yong Beom Cho, Seong Hyeon Yun, Woo Yong Lee, Ho-Kyung Chun
J Korean Soc Coloproctol. 2010;26(4):287-292.   Published online August 31, 2010
DOI: https://doi.org/10.3393/jksc.2010.26.4.287
  • 3,333 View
  • 38 Download
  • 5 Citations
AbstractAbstract PDF
Purpose

Oral capecitabine has been used as adjuvant therapy for colorectal cancer patients since the 1990s. Patient-initiated cessation or reduced use of capecitabine occurs widely for various reasons, yet the consequences of these actions are unclear. The present study sought to clarify treatment outcomes in such patients.

Methods

The study included 173 patients who had been diagnosed with stage II or III colon cancer according to the pathologic report after radical surgery at Samsung Medical Center from May 2005 to June 2007 and who had received capecitabine as adjuvant therapy. The patients were divided into groups according to whether the dose was reduced (I, dose maintenance; II, dose reduction) or stopped (A, cycle completion; B, cycle cessation). Recurrence and disease-free survival rates between the two groups each were analyzed.

Results

Of the 173 patients, 128 (74.6%) experienced complications, most frequently hand-foot syndrome (n = 114). Reduction (n = 35) or cessation (n = 18) of medication was most commonly due to complications. Concerning reduced dosage, both groups displayed no statistically significant differences in recurrence rate and 3-year disease-free survival rate. Concerning discontinued medication use, the cycle completion group showed an improved recurrence rate (P = 0.048) and 3-year disease-free survival rate (P = 0.028).

Conclusion

The results demonstrate that maintaining compliance with capecitabine as an adjuvant treatment for colon cancer to preventing complications positively affects patient prognosis.

Citations

Citations to this article as recorded by  
  • The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients
    Doreen Z. Mhandire, Andrew K. L. Goey
    Molecular Diagnosis & Therapy.2022; 26(2): 137.     CrossRef
  • Global Cancer Burden and Natural Disasters: A Focus on Asia’s Vulnerability, Resilience Building, and Impact on Cancer Care
    Roselle De Guzman, Monica Malik
    Journal of Global Oncology.2019; (5): 1.     CrossRef
  • Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer
    Devon J. Boyne, Colleen A. Cuthbert, Dylan E. O’Sullivan, Tolulope T. Sajobi, Robert J. Hilsden, Christine M. Friedenreich, Winson Y. Cheung, Darren R. Brenner
    JAMA Network Open.2019; 2(5): e194154.     CrossRef
  • 5-fluorouracil Toxicity Mechanism Determination in Human Keratinocytes: in vitro Study on HaCaT Cell Line
    Jan Hartinger, Pavel Veselý, Martin Šíma, Irena Netíková, Eva Matoušková, Luboš Petruželka
    Prague Medical Report.2017; 118(4): 128.     CrossRef
  • An exploratory study to identify risk factors for the development of capecitabine‐induced Palmar Plantar Erythrodysesthesia (PPE)
    Annie Law, Sue Dyson, Denis Anthony
    Journal of Advanced Nursing.2015; 71(8): 1825.     CrossRef

Ann Coloproctol : Annals of Coloproctology Twitter Facebook
TOP